Evolus, Inc. (EOLS) |
8.44 0.19 (2.3%)
|
03-24 16:00 |
Open: |
8.2 |
Pre. Close: |
8.25 |
High:
|
8.48 |
Low:
|
8.13 |
Volume:
|
189,013 |
Market Cap:
|
476(M) |
|
|
Technical analysis |
as of: 2023-03-24 4:25:40 PM |
Overall:
|
|
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
Target: |
Six months: 10.55 One year: 11.35 |
Support: |
Support1: 7.92 Support2: 6.59 |
Resistance: |
Resistance1: 9.03 Resistance2: 9.72 |
Pivot: |
8.55  |
Moving Average: |
MA(5): 8.36 MA(20): 8.67 
MA(100): 8.37 MA(250): 9.86  |
MACD: |
MACD(12,26): -0.3 Signal(9): -0.2  |
Stochastic oscillator: |
%K(14,3): 26.8 %D(3): 27.7  |
RSI: |
RSI(14): 44  |
52-week: |
High: 14.34 Low: 6.51 |
Average Vol(K): |
3-Month: 552 (K) 10-Days: 405 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EOLS ] has closed above bottom band by 40.9%. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
8.48 - 8.53 |
8.53 - 8.57 |
Low:
|
8.03 - 8.08 |
8.08 - 8.12 |
Close:
|
8.37 - 8.44 |
8.44 - 8.51 |
|
Company Description |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California. |
Headline News |
Mon, 13 Mar 2023 Hsbc Holdings PLC Cuts Stake in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Mon, 13 Mar 2023 Analysts Set Expectations for Evolus, Inc.'s Q4 2023 Earnings ... - MarketBeat
Sat, 11 Mar 2023 Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 08 Mar 2023 After-Hours Earnings Report for March 8, 2023 : MDB, DADA, VET ... - Nasdaq
Wed, 08 Mar 2023 Evolus Reports Fourth Quarter and Full Year 2022 Results and ... - Business Wire
Wed, 08 Mar 2023 Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Drug Manufacturers—Specialty & Generic |
Shares Out. |
56 (M) |
Shares Float |
33 (M) |
% Held by Insiders
|
24.2 (%) |
% Held by Institutions
|
58.1 (%) |
Shares Short
|
2,210 (K) |
Shares Short P.Month
|
2,220 (K) |
Stock Financials |
EPS
|
-1.33 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
0.33 |
Profit Margin (%)
|
-50.1 |
Operating Margin (%)
|
-38.8 |
Return on Assets (ttm)
|
-16.6 |
Return on Equity (ttm)
|
-148.3 |
Qtrly Rev. Growth
|
25.8 |
Gross Profit (p.s.)
|
1.64 |
Sales Per Share
|
2.63 |
EBITDA (p.s.)
|
-0.96 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-85 (M) |
Levered Free Cash Flow
|
-54 (M) |
Stock Valuations |
PE Ratio
|
-6.4 |
PEG Ratio
|
-1.3 |
Price to Book value
|
25.57 |
Price to Sales
|
3.2 |
Price to Cash Flow
|
-5.61 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|